NCT01239004View on ClinicalTrials.gov

Colesevelam Treatment for Impaired Fasting Glucose During Niacin Therapy

PHASE4CompletedINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

August 31, 2011

Study Completion Date

August 31, 2011

Conditions
DyslipidemiaHyperlipidemiaHyperglycemia
Interventions
DRUG

Placebo

6 tablets daily, with up to 2000 mg niacin and 325 mg aspirin daily, for 12 weeks

DRUG

Colesevelam

6 tablets (3750 mg total) daily, with up to 2000 mg niacin and 325 mg aspirin daily, for 12 weeks

Trial Locations (4)

Unknown

Radiant Research, Chicago

Kansas City

Minneapolis

St Louis

Sponsors

Lead Sponsor

Radiant Research
All Listed Sponsors
lead

Radiant Research

OTHER

NCT01239004 - Colesevelam Treatment for Impaired Fasting Glucose During Niacin Therapy | Biotech Hunter | Biotech Hunter